Targeting cancer with the anticancer molecule Thymoquinone: Potential for clinical translation

Hala Gali-Muhtasib

American University of Beirut, Lebanon, E-mail: amro@aub.edu.lb

Abstracts:

Introduction: Chemotherapeutic operators make numerous unfriendly reactions. As of now, there is a pattern in scanning for anticancer synthetic concoctions in characteristic sources, as regular items are generally thought to be less harmful and produce negligible symptoms. Medications from characteristic sources have been utilized generally for a huge number of years in different pieces of the world. Researchers have focused on numerous conventional or society medications in equal of present day medication to distinguish and separate dynamic elements for the medication improvement. Thymoquinone (2-methyl-5-isopropyl-1,4-benzoquinone) is a phytochemical compound found in dark cumin (Nigella sativa) with a long history of restorative use. The dark cumin seeds have a remarkable history in customary medication rehearses mostly in South and South-eastern Asia, Arab, Africa and Mediterranean districts. In old Egypt, Greece and Turkey, dark cumin seeds were regularly used to treat various infections and infirmities. The two seeds and oil from Nigella sativa plants are utilized in therapeutic purposes, and they are known for their anticancer, antidiabetic, antihypertensive, antimicrobial, pain relieving, immunomodulatory, calming, spasmolytic, hepato-defensive, renal-defensive, gastro-defensive, bronchodilative and cell reinforcement exercises. Dark cumin seeds and oil are otherwise called 'Prophetic medication', as the Islamic prophet has regarded its high potential as medication. Despite advances in cancer therapeutics, cancer is still the second leading cause of death worldwide. Chemotherapy resistance is implicated in the increased death rates among cancer patients.

Methodology & Theoretical Orientation: It is essential to adopt novel strategies for the discovery of anticancer agents that combat resistance mechanisms and are less toxic. There is growing interest in "safe" molecules from plant sources that have anticancer activities against human cancers. One such molecule is Thymoquinone (TQ), the main bioactive component of black seed Nigella sativa.

Findings: Evidence-based research by numerous scientists including ours has shown that TQ targets many types of cancer. Pharmacokinetic contemplates indicated that thymoquinone is quickly dispensed with and gradually assimilated, and thus thymoquinone has less bioavailability. The determined supreme bioavailability of thymoquinone was accounted for ~58% with a slack time of ~23 min by Alkharfy et al. A few compound subsidiaries have been utilized to improve the pharmacokinetic conduct of thymoquinone to build the bioavailability. Thymoquinone-4-α-linolenoylhydrazone and thymoquinone-4-palmitoylhydrazone was found to repress cell expansion subject to p53 status by actuating the cell cycle inhibitor p21. Additionally the advancement of nanoparticles has made a striking methodology in thymoquinone conveyance, which may be exceptionally successful in upgrading bioavailability. Thymoquinone-stacked liposomes (TQ-LP) and thymoquinone stacked in liposomes changed with Triton X-100 (XLP) with breadths of around 100 nm were found to look after soundness, improve bioavailability and keep up thymoquinone's anticancer action. Embodiment of TQ into nanoparticles with 97.5% proficiency in biodegradable nanoparticulate definition dependent on poly(lactide-co-glycolide) (PLGA) and stabilizer polyethylene glycol (PEG)- 5000 upgrades its enemy of proliferative, calming, and...
chemosensitizing impacts. Thymoquinone bundled in nanoparticles have been demonstrated progressively helpful to improve bioavailability, which is called 'nanochemoprevention' or 'nano-chemotherapy'.

A twofold mesoporous center shell silica circles (DMCSSs) stacked with thymoquinone was discovered more successful in actuating malignancy cell apoptosis than free thymoquinone, because of the moderate arrival of the medication from the mesoporous structure. In any case, contemplates uncovered that the fluid solvency of thymoquinone is certainly not a significant deterrent for the medication definitions, as it has impressive water dissolvability (> 500 μg/mL), which might be sufficient to apply pharmacologic impacts after parenteral course organization. Thymoquinone-stacked nanostructured lipid bearer (TQ-NLC) has been created to improve its bioavailability (end half-life ~5 hours), which can display cytotoxicity against malignant growth cell lines by prompting apoptosis and cell cycle capture. Bhattacharya et al. created thymoquinone-epitomized nanoparticles utilizing biodegradable, hydrophilic polymers, as polyvinylpyrrolidone and polyethyleneglycol to beat thymoquinone's poor dissolvability, warm and light affectability, and negligible fundamental bioavailability, which can significantly improve the malignant growth treatment's proficiency. This small and relatively non-toxic natural molecule is capable of modulating key signaling pathways that cause cancer progression. TQ also increases the efficacy of clinically used anticancer agents such as 5-fluorouracil, cisplatin, and doxorubicin and decreases their in vivo toxicity when combined with these drugs.

**Conclusion & Significance:** Thymoquinone is apparent as a strong anticancer particle by managing various atomic systems, and it can possibly be a decent restorative little particle in the anticipation and treatment of malignant growth. Presently is the correct chance to consider clinical preliminaries, explicitly Phase I preliminaries. For thymoquinone conveyance, it tends to be directed in an exceptionally low dose embodied in a lipophilic biogels or nanoparticles, or be utilized in blend with other set up chemotherapeutic medications. In the meantime, research center examinations should proceed for better comprehension of atomic instrument of thymoquinone activity to create strong analogs with restricted reactions and an increasingly advantageous medication conveyance framework, at last improving malignant growth the executives framework. Considering the potential of TQ to target cancer cells, my presentation will focus on its chemical, pharmacological and biological properties that make it an interesting molecule for clinical translation. I will also present recent advances in TQ nanoformulation and analog design and discuss the current state of our knowledge of TQ??s adjuvant potential in vivo and highlight its ability to modulate the hallmarks of cancer.

*This work is partly presented at Joint Event on 2nd Annual summit on Cell Signaling and Cancer Therapy & Cell Metabolism and Cytopathology*